- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07708896
Evolution of Chronic Inflammatory Skin Diseases (EPICA)
monocentric retrospective-prospective observational study evaluating the clinical evolution of common chronic inflammatory skin diseases, including atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study will collect demographic, clinical, therapeutic, and validated clinimetric data from patients aged ≥12 years. Its primary aim is to describe changes in disease severity over time. Secondary objectives include identifying demographic, clinical, and treatment-related predictors of moderate-to-severe disease and unfavorable outcomes. Data will cover a 7-year retrospective period and a 10-year prospective follow-up.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Ketty Peris
- Telefoonnummer: +390630155701
- E-mail: ketty.peris@policlinicogemelli.it
Studie Locaties
-
-
-
Rome, Italië, 00168
- Werving
- Fondazione Policlinico Agostino Gemelli IRCCS
-
Contact:
- Ketty Peris, Prof
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
patients affected with inflammatory skin conditions including atopic dermatitis, prurigo nodularis, Hidradenitis suppurativa, psoriasis
Beschrijving
Inclusion Criteria:
- Age ≥12 years.
- Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
- Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.
Exclusion Criteria:
- Age <12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
- Refusal or inability to understand and sign the informed consent form.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: OTHER
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change Over Time in Eczema Area and Severity Index (EASI)
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Eczema Area and Severity Index (EASI) in participants with atopic dermatitis. EASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in SCORing Atopic Dermatitis (SCORAD)
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in SCORing Atopic Dermatitis (SCORAD) in participants with atopic dermatitis. SCORAD ranges from 0 to 103, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Patient-Oriented Eczema Measure (POEM)
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Patient-Oriented Eczema Measure (POEM) in participants with atopic dermatitis. POEM ranges from 0 to 28, with higher scores indicating greater patient-reported disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Psoriasis Area and Severity Index (PASI)
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Psoriasis Area and Severity Index (PASI) in participants with psoriasis. PASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hand Eczema Severity Index (HECSI)
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Hand Eczema Severity Index (HECSI) in participants with chronic hand eczema. HECSI ranges from 0 to 360, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Investigator's Global Assessment for Prurigo Nodularis
Tijdsspanne: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change in Investigator Global Assessment (IGA) in patients with prurigo nodularis |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Itch Numerical Rating Scale (NRS)
Tijdsspanne: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in itch intensity assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, where 0 indicates no itch and 10 indicates the worst imaginable itch. Higher scores indicate worse itch. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Sleep Numerical Rating Scale (NRS)
Tijdsspanne: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in sleep disturbance assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, with higher scores indicating greater sleep disturbance. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Dermatology Life Quality Index (DLQI)
Tijdsspanne: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Dermatology Life Quality Index (DLQI). Scores range from 0 to 30, with higher scores indicating greater impairment in dermatology-related quality of life. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hurley Stage
Tijdsspanne: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in hidradenitis suppurativa severity according to Hurley staging. Hurley stage ranges from Stage I to Stage III, with higher stages indicating more severe disease. |
baseline and every 16 ± 4 weeks, up to 120 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Ketty Peris, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 27085
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .